Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Gamida Cell Ltd. $50 Million Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering…
Davis Polk Advises Laboratorios Farmacéuticos Rovi, S.A. on Its €80 Million Follow-On Offering
Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of…
Aetna receives DOJ approval of $77 billion acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed…
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed…
AtriCure, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
Kodiak Sciences Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with the $90 million initial public offering of common stock by Kodiak…
Kala Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with…
Cipla Quality Chemical Industries Limited Initial Public Offering and USE Listing
Davis Polk advised the bookrunner in connection with the initial public offering of Cipla Quality Chemical Industries…
Davis Polk Advises Shire on Its $2.325 Billion Concurrent Tender Offers
Davis Polk advised Shire plc on concurrent tender offers by Baxalta Incorporated and Shire Acquisitions Investments Ireland…
AbbVie Inc. $6 Billion Senior Notes Offering
Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of …